Navigation Links
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Date:10/5/2009

idates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                          Media
    info@peregrineinc.com                              Barbara Lindheim
    (800) 987-8256                                     (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Milpitas, Calif. (PRWEB) March 03, 2015 ... risk management excellence were honored by the Global ... annual event which took place on Wednesday, February 25th, ... , The GSCRC was formed to bring together supply ... thought leaders to advance the professional discipline through opportunities ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
(Date:3/3/2015)... , March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, announced today that it ... on March 12, 2015 after the market close. The Company ... that day. Interested parties may access the ... (484) 756-4262 internationally, and using conference ID 98449349.  ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... HUBBARD, Ohio, Jan. 10, 2012   NanoLogix Inc. (PINK ... antibiotic sensitivity determination of live bacteria announces that has instructed ... submittal to the US FDA . The applications are ... for approval for use as a BSL-3 test process for ...
... and BEIJING, Jan. 10, 2012 The global fight ... Aeras and the China National Biotec Group (CNBG) announce ... new tuberculosis (TB) vaccines. The agreement between the leading ... biotechnology corporation in China signals a commitment by both ...
... in Spanish . Miguel A. Cazalilla, ... the Donostia International Physics Center (DIPC), together with other four ... was recently invited to write a review article that has ... Modern Physics of the American Physical Society, where only ...
Cached Biology Technology:NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents 2NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents 3NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents 4Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 2Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 3Smaller and more powerful electronics requires the understanding of 'quantum jamming' physics 2
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... responsible for the plague and some forms of food poisoning ... way, according to a new study in the September 8, ... , The researchers found that these bacteria, which belong to ... unrelated mammalian enzyme. That copycat protein blocks host cells' capacity ...
... yeast, University of Wisconsin-Madison researchers have uncovered novel functions of ... master regulatory switch -- a control that determines gene activity ... neurological disorders. , The work, published in the Dec. 8 ... in a single gene can have widespread effects on regulation ...
... Proteins called H2AX act as "first aid" to DNA, among ... world's most powerful light microscope (the only one of ... is distributed in the cell nucleus: in clusters, directing the ... it is really needed. , Many biological processes lie ...
Cached Biology News:Study illuminates how the plague bacteria causes disease 2Study illuminates how the plague bacteria causes disease 3From a lowly yeast, researchers divine a clue to human disease 2Nanoscale microscope sheds first light on gene repair 2
Request Info...
Request Info...
Loading Buffer...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Biology Products: